Moderna's combination skin cancer therapy receives FDA's breakthrough tag

World
23-02-2023 | 06:27
High views
Share
LBCI
Share
LBCI
Whatsapp
facebook
Twitter
Messenger
telegram
telegram
print
Moderna's combination skin cancer therapy receives FDA's breakthrough tag
Whatsapp
facebook
Twitter
Messenger
telegram
telegram
print
0min
Moderna's combination skin cancer therapy receives FDA's breakthrough tag

Moderna Inc (MRNA.O) said on Wednesday its experimental personalized mRNA skin cancer vaccine in combination with Merck & Co Inc's (MRK.N) drug Keytruda has received breakthrough therapy designation from US regulators as an additional treatment for high-risk patients.

Shares of Moderna rise 2.5% to $164 after the market.

The breakthrough tag is granted by the US Food and Drug Administration (FDA) based on data from a mid-stage study of the drug that showed the therapy reduced risk of skin cancer's recurrence or death by 44% compared with Keytruda alone.

The FDA's breakthrough therapy designation is granted to expedite the development and review of drugs that are intended to treat a serious condition.

The companies said they plans to initiate a late-stage study in adjuvant treatment of melanoma in 2023.

REUTERS
 

Moderna

Skin

Cancer

Therapy

Treatment

FDA

Download now the LBCI mobile app
To see the latest news, the latest daily programs in Lebanon and the world
Google Play
App Store
We use
cookies
We use cookies to make
your experience on this
website better.
Accept
Learn More